Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes

被引:9
作者
Zheng, Yaguo [1 ,2 ]
Yang, Tao [1 ,2 ]
Chen, Guo [1 ,2 ]
Hu, Enci [1 ,2 ]
Gu, Qing [1 ,2 ]
Xiong, Changming [1 ,2 ]
机构
[1] Chinese Acad Med Sci, State Key Lab Cardiovasc Dis, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing 100037, Peoples R China
[2] Peking Union Med Coll, Beijing 100037, Peoples R China
关键词
Pulmonary arterial hypertension; Meta-analysis; Randomized controlled trials; Prostanoids; CONTINUOUS INTRAVENOUS EPOPROSTENOL; RANDOMIZED CONTROLLED-TRIALS; 6-MINUTE WALK DISTANCE; INHALED ILOPROST; PROSTACYCLIN ANALOG; ORAL TREPROSTINIL; DOUBLE-BLIND; DIAGNOSIS; EFFICACY; INFUSION;
D O I
10.1007/s00228-013-1583-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prostanoids have played an important role in the treatment of pulmonary arterial hypertension (PAH). However, whether prostanoid therapy provides a survival advantage is still not clear. The aim of this meta-analysis was to evaluate the efficacy and safety of prostanoids in PAH, focusing on the improvement in overall survival. Trials were identified from the Cochrane Library, EMBASE, and PUBMED databases. We calculated risk ratios (RR) for dichotomous data and weighted mean differences with 95 % confidence intervals (CI) for continuous data. Fourteen trials with a total of 2,244 adult patients (1,189 patients in the prostanoid treatment group and 1,055 patients in the placebo group) were included in the meta-analysis. All-cause mortality rate in the control group was 4.17 %. In a 13.4-week follow-up, prostanoid treatment was associated with a 44 % reduction in mortality (RR 0.56; 95 % CI 0.35-0.88; P = 0.01).Subgroup analysis suggested that only treatment with intravenous prostanoids provided a survival benefit. Compared with placebo, prostanoids significantly reduced clinical worsening (RR 0.60; 95 % CI 0.46-0.80; P = 0.0003), increased the 6-min walk distance by 27.95 m, reduced mean pulmonary arterial pressure and pulmonary vascular resistance, and increased the cardiac index and mixed venous oxygen saturation. However, patients receiving prostanoid treatment showed a much higher incidence (RR 3.25; 95 % CI 2.07-5.10; P < 0.00001) of withdrawal due to its adverse effects. The results of this meta-analysis suggest that treatment with prostanoids improves the survival of patients with PAH.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 37 条
[1]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[2]   Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis [J].
Bai, Yuanyuan ;
Sun, Lan ;
Hu, Shengshou ;
Wei, Yingjie .
CARDIOLOGY, 2011, 120 (03) :157-165
[3]   Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil [J].
Barst, R. J. ;
Galie, N. ;
Naeije, R. ;
Simonneau, G. ;
Jeffs, R. ;
Arneson, C. ;
Rubin, L. J. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) :1195-1203
[4]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[5]   Beraprost therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
McLaughlin, V ;
Tapson, V ;
Oudiz, R ;
Shapiro, S ;
Robbins, IM ;
Channick, R ;
Badesch, D ;
Rayburn, BK ;
Flinchbaugh, R ;
Sigman, J ;
Arneson, C ;
Jeffs, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125
[6]   An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry [J].
Benza, Raymond L. ;
Miller, Dave P. ;
Barst, Robyn J. ;
Badesch, David B. ;
Frost, Adaani E. ;
McGoon, Michael D. .
CHEST, 2012, 142 (02) :448-456
[7]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[8]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[9]   Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials [J].
Gabler, Nicole B. ;
French, Benjamin ;
Strom, Brian L. ;
Palevsky, Harold I. ;
Taichman, Darren B. ;
Kawut, Steven M. ;
Halpern, Scott D. .
CIRCULATION, 2012, 126 (03) :349-+
[10]   Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:: With pulmonary arterial hypertension:: A randomized, double-blind, placebo-controlled trial [J].
Galiè, N ;
Humbert, M ;
Vachiéry, JL ;
Vizza, CD ;
Kneussl, M ;
Manes, A ;
Sitbon, O ;
Torbicki, A ;
Delcroix, M ;
Naeije, R ;
Hoeper, M ;
Chaouat, A ;
Morand, S ;
Besse, B ;
Simonneau, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (09) :1496-1502